On July 23, 2026 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, reported that an abstract for the investigator-initiated EFTISARC-NEO Phase II trial evaluating its first-in-class MHC Class II agonist, eftilagimod alfa ("efti"), has been accepted for presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, taking place 23–27 October 2026 in Madrid, Spain.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstract reports health-related quality of life (HRQoL) data from EFTISARC-NEO. Details of the accepted abstract and poster are as follows:
Title Health-related quality of life (HRQoL) during neoadjuvant treatment with eftilagimod alfa, pembrolizumab and radiotherapy in patients with soft tissue sarcoma (STS) – results from EFTISARC-NEO trial
Trial EFTISARC-NEO (investigator-initiated Phase II; NCT06128863)
Session category ePoster
First Author Pawel Teterycz, M.D., Maria Skłodowska-Curie National Research Institute of Oncology (MSCNRIO), Warsaw, Poland
Presentation # 3788eP
Abstract online Monday, 19 October 2026 at 00:05 CEST (ESMO website)
The full abstract will be published on the ESMO (Free ESMO Whitepaper) Congress 2026 website on Monday, 19 October 2026. The presentation will subsequently be made available on Immutep’s website.
(Press release, Immutep, JUL 23, 2026, View Source;v=undefined [SID1234669397])